Enhanced metabolism of 1-β-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of down syndrome children with acute myeloid leukemia

Blood

Volumn 87, Issue 8, 1996, Pages 3395-3403

  Taub, Jeffrey W ^a   Matherly, Larry H ^b   Stout, Mark L ^b   Buck, Steven A ^b   Gurney, James G ^b   Ravindranath, Yaddanapudi ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; CYTARABINE; DOUBLE STRANDED DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHROMOSOME 21; CONTROLLED STUDY; DOWN SYNDROME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PYRIMIDINE METABOLISM;

EID: 0029939156     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.8.3395.bloodjournal8783395     Document Type: Article

References (53)

1. Rosner F, Lee S: Down syndrome and acute leukemia: Myeloblastic or lymphoblastic; report of forty-three cases and review of literature. Am J Med 53:203, 1972
2. Robison L: Down syndrome and leukemia Leukemia 6:5, 1992 (suppl 1)
3. Abdel-Mageed AH, Ragab AJ, Shuster J, Pullen J, Van Eys J, Sullivan MP, Boyett J, Borowitz M, Frankel LS, Crist W: Children with Down syndrome and acute lymphocytic leukemia (DS-ALL): Presenting features and outcome of therapy: A Pediatric Oncology Group study. Cancer 67:1057, 1991
4. Peeters M, Poon A: Down syndrome and leukaemia: Unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr 146:416, 1987
5. Lejeune J, Peeters M, Rethore M-O, de Blois M-C: Homocysteine and the methotrexate toxicity in trisomy 21. Cancer Chemother Pharmacol 27:331, 1991
6. Ueland PM, Refsum FH, Christensen B. Methotrexate sensitivity in Down Syndrome: A hypothesis. Cancer Chemother Pharmacol 25:384, 1990
7. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK, Land V, Steuber CP, Weinstein H: Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML study 8498. Blood 80:2210, 1992
8. Zipursky A, Poon A, Doyle J: Leukemia in Down Syndrome: A review. Pediatr Hematol Oncol 9:139, 1992
9. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol 15:392, 1993
10. Novakovic B: US childhood cancer survival, 1973-1987. Med Pediatr Oncol 23:480, 1994
11. Boulad F, Kernan NA: Treatment of childhood acute non-lymphoblastic leukemia: A review. Cancer Invest 11:534, 1993
12. Slordahl SH, Gustafsson G, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Lie S: Down's syndrome (DS) and acute myelogenous leukemia (AML). A population based study in the five Nordic countries. Med Pediatr Oncol 20:373a, 1992 (abstr)
13. Kojima S, Kato K, Matsuyama T, Yoshikawa T, Horibe K: Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome. Blood 81:3164, 1993 (letter)
14. Zipursky A, Thorner P, Harven ED, Christensen H, Doyle J: Myelodysplasia and acute megakaryoblastic leukemia in Down's Syndrome. Leuk Res 18:163, 1994
15. Creutzig U, Niemeyer C, Stollmann-Gibbels B, Ritter J, Harbott J: Prognosis of children with Down's syndrome and acute myelogenous leukemia. Proc Am Assoc Clin Oncol 14:1044a, 1995 (abstr)
16. Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann, Smithson W, Srivastava A, Tannous R, Buckley CM, Whitt JK, Wolff L, Lampkin BC: Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Childrens Cancer Group study. J Clin Oncol 12:2367, 1994
17. Lie SO, Berglund G, Gustafsson G, Jonmundsson G, Siimes M, Yssing M: High-dose ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia, in Büchner J, Schellong G, Hiddemann W, Ritter J (eds): Acute Leukemias II. Berlin Heidenberg, Germany, Springer-Verlag, 1990, p 215
18. Taub JW, Ravindranath Y: Superior disease free survival of Down Syndrome children with acute myeloid leukemia associated with enhanced sensitivity to cytarabine and daunorubicin-a hypothesis. Proceedings of the Tenth Annual National Down Syndrome Society Science Research Conference, April 10-13, 1994, Charleston, SC
19. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MWJ, Heyenbrok MW, Hahlen K, Veerman AJP: In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76.2327, 1990
20. Otsuka F, Tarone RE, Seguin LR, Robbins JH: Hypersensitivity to ionizing radiation in culture cells from Down Syndrome patients. J Neural Sci 69:103, 1985
21. Lemieux N, Malfoy B, Forrest GL: Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells. Genomics 15:169, 1993
22. White DL, Hutchins CJ, Haylock DN, Turczynowicz S, Bishop A, To LB, Hughes TP, Juttner CA: Direct analysis of FACS-sorted hemopoiettc cell fractions using FISH. Biotechniques 18:818, 1995
23. Shapiro HM: Practical Flow Cytometry. New York, NY, Wiley-Liss, 1988
24. Hoang T, McCulloch EA: Production of leukemic blast growth factor by a human bladder carcinoma cell line. Blood 66:748, 1985
25. Lacombe F, Belloc F, Dumain P, Puntous M, Makhoul PC, Saux M-C, Bernard P, Boisseau MR, Reiffers J: Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry. Blood 84:716, 1994
26. Hanks JH, Wallace RE. Relation of oxygen and temperature in the preservation of tissues by refrigeration. Proc Soc Exp Biol Med 71:196, 1949
27. Zittoun J, Marquet J, David JC, Maniey D, Zittoun R: A study of the drug mechanisms of cytotoxicity of ara-C on three leukemic cell lines. Cancer Chemother Pharmacol 24:251, 1989
28. Peterson GL: A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83:346, 1977
29. Boos J: A simple isocratic ion-pair high performance liquid Chromatographic determination of 1-β-D-arabinofuranosylcytosine 5-triphosphate for intracellular monitoring and in vitro incubation assays. J Pharm Biomed Anal 9:47, 1991
30. Skoog KL, Nordenskjöld BA, Bjursell KG: Deoxyribonucleoside-triphosphate pools and DNA synthesis in synchronized hamster cells. Eur J Biochem 33:428, 1973
31. Birnboim HC, Jevcak JJ: Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res 41:1889, 1981
32. Tanizawa A, Kubota M, Takimoto T, Kito T, Akiyama Y, Kiriyama Y, Mikawa H: Synergistic effect of methotrexate and 1-β-D-arabinofuranosylcytosine on the generation of DNA strand breaks in a human promyelocytic leukemia cell line. Leuk Res 13:151, 1989
33. Hall Jr. AH, Eanes RZ, Waymack Jr. PP, Patterson RM: Acute effects of a superoxide radical-generating system on DNA double-strand stability in Chinese hamster ovary cells. Mutat Res 198:161, 1988
34. Fisher LD, van Bell G: Biostatistics: A methodology for the health sciences. New York, NY, Wiley, 1993
35. Heinemann V, Jehn U: Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside. Leukemia 4:790, 1990
36. Plunkett W, Liliemark JO, Estey E, Keating MJ: Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 14:159, 1987 (suppl 1)
37. Kohl U, Schwabe D, Visschedyk K, Linnert H, Kornhuber B: Formation of cytosine-arabinoside-5′-triphosphate in malignant lymphoblasts and normal lymphocytes with reference to their drug sensitivity. Leukemia 9:528, 1995 (abstr)
38. Chadefaux B, Rethore MO, Raoul O, Ceballos I, Poissonnier M, Gilgenkrantz S, Allard D: Cystathionine beta synthase: Gene dosage effect of trisomy 21. Biochem Biophys Res Commun 128:40, 1988
39. Chadefaux B, Ceballos I, Hamet M, Coude M, Poissonnier M, Kamoun P, Allard D: Is absence of atheroma in Down syndrome duc to decreased homocysteine levels? Lancet 1:741, 1988 (letter)
40. Candide C, Mazière C, Mazière JC, Polonovski J, Lejeune J: Méthylation des phospholipides dans les fibroblastes de patients atteints de trisomie 21. Ann Genet 30:213, 1987
41. Krumdieck CL: Role of folate deficiency in carcinogeneisis, in Butterworth CE, Hutchinson ML (eds): Nutritional Factors in the Induction and Maintenance of Malignancy. New York, NY, Academic, 1983, p 225
42. Scott JM, Weir DG: The methyl folate trap. Lancet 1:337, 1981
43. Damon LE, Cadman EC. The metabolic basis for combination chemotherapy. Pharmacol Ther 38:73, 1988
44. Aimi J, Qiu H, Williams J, Zalkin H, Dixon JE: De novo purine nucleotide biosynthesis: Cloning of human and avian cDNAs encoding the trifunctional glycinamide ribonucleotide synthetase-aminoimidazole ribonucleotide synthetase-glycinamide ribonucleotide transformylase by functional complementation in E. coli. Nucleic Acids Res 18:6665, 1991
45. Beardsley GP, Moroson BA, Taylor ED, Moran RG: A new folate therapy antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328, 1989
46. Gandhi V, Estey EH, Keating M, Plunkett W: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia. J Clin Oncol 11.116, 1993
47. Xu Y-Z, Huang P, Plunkett W: Functional compartmentation of dCTP pools: Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts. J Biol Chem 270:631, 1995
48. -1. Cancer Res 47:3672, 1987
49. Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS: Pharmacodynamic and DNA methylation studies of high-dose 1-β-D-arabinofuranosylcytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia. Cancer Chemother Pharmacol 24:203, 1989
50. Capizzi RL, White JC, Powell BL, Perrino F: Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin Hematol 28:54, 1991 (suppl 4)
51. Kucera GL, Capizza RL: 1-β-D-arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephospho-transferase and not via cytidylyltransferase. Cancer Res 52:3886, 1992
52. Schaison G, Daniel MT, Berger R, Barunchel A: De novo acute megakaryoblastic leukemia (AMKL) in children. A study of 22 cases. Blood 76:316a, 1990 (abstr)
53. Ribeiro RC, Oliveira MS, Fairclough D, Hurwitz C, Mirro J, Behm JG, Head D, Silva ML, Raimondi SC, Crist WM: Acute megakaryoblastic leukemia in children and adolescents: A retrospective analysis of 24 cases. Leuk Lymphoma 10:299, 1993 (review)